Subscribe to RSS
DOI: 10.1055/s-0038-1651054
Treatment of Hereditary Protein C Deficiency with Stanozolol
Publication History
Received 17 June 1986
Accepted after revision 14 October 1986
Publication Date:
06 July 2018 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/198701/lookinside/thumbnails/10-1055-s-0038-1651054-1.jpg)
Summary
Five type I protein C deficient male patients received 5 mg stanozolol b.i.d. during 4 weeks. After four weeks of treatment plasma protein C activity increased from 0.42 to 0.74 U/ml and protein C antigen from 0.49 to 0.75 U/ml. This approximately 1.6 fold increase in plasma protein C was accompanied by an increase in factor II antigen (1.5 fold), factor V activity (1.6 fold), factor X antigen (1.1 fold), antithrombin III antigen (1.3 fold) and heparin cofactor II antigen (1.5 fold), while the concentration of factor VII, factor VIII, and factor IX activity, and of protein S antigen remained unchanged. Prothrombin fragment F1+2, measured in two patients, increased 1.3 fold. In addition to its effect on procoagulant and anticoagulant factors stanozolol had profibrinolytic effects, reflected in an increase in tPA activity and in the concentration of plasminogen. These data indicate that in type I protein C deficient patients stanozolol increases the concentrations of both procoagulant and anticoagulant factors and favours fibrinolysis. The efficacy of stanozolol in preventing thrombotic disease in type I protein C deficient patients, however, remains to be established. During the four weeks of stanozolol treatment no thrombotic manifestations were observed in the protein C deficient patients.
-
References
- 1 Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-1373
- 2 Broekmans AW, Veltkamp JJ, Bertina RM. Congenital protein C deficiency and venous thrombo-embolism. A study of three Dutch families. New Engl J Med 1983; 309: 340-344
- 3 Pabinger-Fasching I, Bertina RM, Lechner K, Niessner H, Kominger C. Protein C deficiency in two Austrian families. Thromb Haemostas 1983; 50: 810-813
- 4 Horellou MH, Conard J, Bertina RM, Samama M. Congenital protein C deficiency and thrombotic disease in nine French families. Br Med J 1984; 289: 1285-1287
- 5 Broekmans AW. Hereditary protein C deficiency. Haemostasis 1985; 15: 233-240
- 6 Broekmans AW, Bertina RM, Loeliger EA, Hofmann V, Klingemann HG. Protein C and the development of skin necrosis during anticoagulant therapy. Thromb Haemostas 1983; 49: 251
- 7 McGehee WG, Klotz TA, Epstein DJ, Rapaport SI. Coumarin necrosis associated with hereditary protein C deficiency. Ann Int Med 1984; 100: 59-60
- 8 Samama M, Horellou MH, Soria J, Conard J, Nicolas G. Successful progressive anticoagulation in a severe protein C deficiency and previous skin necrosis at the initiation of oral anticoagulant treatment. Thromb Haemostas 1984; 51: 132-133
- 9 Pabinger-Fasching I, Deutsch E. Protein C deficiency in Austria. Sem Thromb Hemost 1985; 11: 347-351
- 10 Loeliger EA, Broekmans AW. Drugs affecting blood clotting, fibrinolysis and hemostasis. In: Meyler’s Side Effects of drugs. Dukes MNG. (ed). Amsterdam, Excerpta Medica; 1984. 10 648-693
- 11 Kluft C, Bertina RM, Preston FE, Malia RG, Blarney SL, Lowe G DO, Forbes CD. Protein C, an anticoagulant protein, is increased in healthy volunteers and surgical patients after treatment with stanozolol. Thromb Res 1984; 33: 297-304
- 12 Bertina RM, Broekmans AW, Linden I Kvan der, Mertens K. Protein C deficiency in a Dutch family with thrombotic disease. Thromb Haemostas 1982; 48: 1-5
- 13 Bertina RM, Broekmans AW, Krommenhoek-van Es C, Van Wijngaarden A. The use of a functional and immunologic assay for plasma protein C in the study of the heterogeneity of congenital protein C deficiency. Thromb Haemostas 1984; 51: 1-5
- 14 Bertina RM, Van Wijngaarden A, Reinalda-Poot J, Poort SR, Born V JJ. Determination of plasma protein S - the protein cofactor of activated protein C. Thromb Haemostas 1985; 53: 268-272
- 15 Friberger P, Knos M. Plasminogen determination in human plasma. In: Chromogenic peptide substrate. Scully M, Kakkar VV. (eds). 128-139 Churchill Livingstone; Edinburgh: 1979
- 16 Verheijen JH, Mullaart E, Chang G TG, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurement in plasma. Thromb Haemostas 1982; 48: 266-269
- 17 Verheijen JH, Chang G TG, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-395
- 18 Kluft C, Vellenga E, Brommer E JP, Wijngaards G. A familial haemorrhagic diathesis in a Dutch family: an inherited deficiency of α2-antiplasmin. Blood 1982; 59: 1169-1180
- 19 Kluft C, Preston FE, Malia RG, Bertina RM, Wijngaards G, Greaves M, Verheijen JH, Dooijewaard G. Stanozolol-induced change in fibrinolysis and coagulation in healthy adults. Thromb Haemostas 1984; 51: 157-164
- 20 Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin-antithrombin complex. Blood 1982; 59: 1086-1097
- 21 Mannucci PM, Bottasso B, Sharon C, Tripodi A. Treatment with stanozolol of type I protein C deficiency in an Italian family. La Ricerca Clin Lab 1984; 14: 673-680
- 22 Broekmans AW, Bertina RM. Hereditary protein C deficiency. In: Biochemical and Medical Aspects of Protein C. Witt I. (ed). Walter de Gruyter; Berlin: 1985: 93-105
- 23 Gonzalez R, Alberca I, Sala N, Vicente V. Protein C deficiency - response to danazol and DDAVP. Thromb Haemostas 1985; 53: 320-322
- 24 Gruppo RA, Francis RB, Marlar RA, Leimer P, Silberstein EB. Discordant protein C deficiency resulting from possible double heterozygosity and its response to danazol. Thromb Haemostas 1985; 54: 142 (Abstr)
- 25 Madanes AE, Farber M. Danazol. Ann Intern Med 1985; 96: 625-630
- 26 Tollefsen DM, Blank M. Detection of a new heparin-dependent inhibitor of thrombin in human plasma. J Clin Invest 1981; 68: 589-596
- 27 Walker FJ. The regulation of activated protein C by a new protein: a possible function for bovine protein S. J Biol Chem 1980; 255: 5521-5524
- 28 Blarney SL, McArdle BM, Burns P, Carter DC, Lowe G DO, Forbes CD. A double-blind trial of intramuscular stanozolol in the prevention of postoperative deep vein thrombosis following elective abdominal surgery. Thromb Haemostas 1984; 51: 71-74
- 29 Winter JH, Fenech A, Bennett B, Douglas AS. Prophylactic antithrombotic therapy with stanozolol in patients with familial antithrombin III deficiency. Br J Haematol 1984; 57: 527-537
- 30 Jarrett P EM, Morland M, Browse NL. The complications of stanozolol and their clinical management. In: Progress in chemical fibrinolysis and thrombolysis. Davidson JF. (ed). Edinburgh: 1979. Churchill Livingstone; 317-321